Donald A. Bergstrom, who serves as President of Research and Development at Relay Therapeutics, Inc. (NASDAQ: RLAY), carried out two separate stock sales on January 27 and 28, 2026, disposing of a combined 21,581 shares of the company's common stock. The trades were executed at prices between $7.62 and $8.45 per share and generated total proceeds of approximately $166,676.
On January 27, Bergstrom sold 18,895 shares at $7.62 per share. After that sale he directly owned 422,733 shares, a total that included 29,121 shares underlying restricted stock units (RSUs). The following day he sold an additional 2,686 shares at $8.45 each. Following the January 28 transaction, his direct ownership stood at 420,047 shares, including 20,049 shares underlying RSUs.
According to company disclosures, the share sales were made to satisfy income tax withholding obligations that arose when RSUs vested and were carried out in accordance with Relay Therapeutics' policies. The transactions do not represent an expansion or reduction of a strategic stake in the business but were tied to the mechanics of equity compensation.
Relay's stock has experienced notable volatility and appreciation in recent months. Over the past six months the shares have gained 111%, though the security was trading at $7.71 at the time of the most recent market quote, below a recent close of $8.50.
Analyst sentiment remains constructive. Coverage maintains a Strong Buy consensus on Relay Therapeutics as the company approaches its next scheduled quarterly results on February 19. Relay's market capitalization is cited at approximately $1.33 billion.
Market and research data referenced alongside the filing indicate that Relay holds more cash than debt on its balance sheet, while also noting that the company is depleting cash reserves at a rapid pace. A Fair Value assessment referenced in that research characterizes the stock as appearing fairly valued at current market levels. The same research service provides additional insights and a comprehensive Pro Research Report that includes further financial-health metrics.
Clinical development progress at the company has also drawn investor attention. Relay reported that zovegalisib, its investigational therapy, demonstrated consistent efficacy in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer in data from the ongoing ReDiscover study. The reported median progression-free survival (PFS) across all patients was 10.3 months. In the subset of second-line patients receiving zovegalisib combined with fulvestrant, median PFS was reported at 11.4 months.
Those clinical updates have been reflected in recent analyst actions. Oppenheimer upgraded Relay Therapeutics from Perform to Outperform and set a $14.00 price target, citing potential advantages for zovegalisib versus a competitor's treatment in an upcoming clinical trial. Citizens reiterated a Market Outperform rating with a $12.00 price target after competitive updates presented at a conference. These developments underscore continuing attention from the investment community as the company advances its clinical program and prepares to report quarterly results.
Summary of the transactions and context
- Transactions: Two sales on January 27 and 28, 2026 totaling 21,581 shares.
- Prices: Trades executed between $7.62 and $8.45 per share.
- Proceeds: Approximately $166,676 in aggregate.
- Post-sale ownership: 422,733 shares (including 29,121 RSUs) after January 27; 420,047 shares (including 20,049 RSUs) after January 28.
- Company metrics and catalysts: 111% six-month share gain, market cap near $1.33 billion, next earnings date February 19; clinical data and analyst actions remain focal points.